Curcumin supplementation in pediatric patients: A systematic review of current clinical evidence

Abstract

This systematic review was designed to determine the clinical efficacy and safety of curcumin supplementation for pediatric patients based on clinical trials in children.We systematically searched electronic databases including PubMed, EMBASE, Web of Science, and Scopus for all studies that investigated curcumin administration in the pediatric population without any time frame limitation. Finally, we identified 16 studies for this review. Clinical efficacy and safety of curcumin were assessed in children with inflammatory and immune disorders (including asthma, inflammatory bowel disease (IBD), and juvenile idiopathic arthritis (JIA)), metabolic disorders, autosomal dominant polycystic kidney disease (ADPKD), cystic fibrosis (CF), tetralogy of Fallot (TOF), and infectious diseases. Curcumin was administered in a wide range of doses (45 mg-4,000 mg daily) and durations (2-48 weeks). Overall, curcumin was well tolerated in all studies and improved the severity of inflammatory and immune disorders and metabolic diseases. However, more studies are needed to clarify the role of curcumin supplementation among children with ADPKD, CF, TOF, and infectious diseases. Because of substantial heterogeneity in methodological quality, design, outcomes, dose, duration of intake, formulations, and study populations across studies, no quantitative analysis was performed. Additional large-scale, randomized, placebo-controlled clinical trials are needed to confirm the results of the conducted studies.

Effect of Curcumin on Attenuation of Liver Cirrhosis via Genes/Proteins and Pathways: A System Pharmacology Study

“…Since ancient times, turmeric has been proposed as a natural cure for a variety of diseases. Curcumin, a natural chemical extracted from the rhizome of Curcuma longa (turmeric), has been demonstrated to have antioxidant, antiproliferative, anti-inflammatory, anticancer, cardioprotective, analgesic, antidiabetic, and hepatoprotective properties [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ]. Numerous in vitro, in vivo, and clinical studies have reported that curcumin may have a beneficial effect on liver cirrhosis [ 2 , 34 , 35 , 36 , 37 , 38 , 39 ].…”

Modulatory properties of curcumin in cancer: A narrative review on the role of interferons

“…In addition to curcuminoids, which are the most important active ingredient in turmeric, sesquiterpenes, diterpenes, and triterpenoids are other such active components that are also present (Abdel‐Lateef et al, 2016). Numerous studies have revealed the safety and efficacy of curcumin in various diseases and pathological conditions (Bavarsad, Barreto, Hadjzadeh, & Sahebkar, 2019; Ganjali et al, 2017; Heidari, Daei, Boozari, Jamialahmadi, & Sahebkar, 2022; Kunnumakkara et al, 2017; Panahi et al, 2017; Panahi, Ghanei, Bashiri, Hajihashemi, & Sahebkar, 2014; Parsamanesh, Moossavi, Bahrami, Butler, & Sahebkar, 2018; Salmaninejad et al, 2019). Another important health benefit of curcumin that has been shown in many clinical studies is its anti‐inflammatory effect (Peng et al, 2021).…”

Curcumin and chemokines: mechanism of action and therapeutic potential in inflammatory diseases

“…Curcumin is a safe phytochemical that elicits a wide range of biological actions in the human body. It shows anti-inflammatory, antioxidant, lipid-modulating, anti-thrombotic, immunomodulatory, hepatoprotective, anti-diabetic, anti-tumor, and neuroprotective actions (Qadir et al 2016;Bavarsad et al 2019;Ghasemi et al 2019;Iranshahi et al 2009;Panahi et al 2017b;Parsamanesh et al 2018;Sahebkar and Henrotin 2016;Alidadi et al 2020;Heidari et al 2022;Vahedian-Azimi et al 2022;Mohammed et al 2021).…”